Inhibikase Therapeutics develops IKT-001, an oral drug candidate for pulmonary arterial hypertension, a rare lung blood vessel disease. It last closed at $1.38 on Nov 17, down 4.83% on the day. The average 12-month price target from 2 analysts is $4.75 (+244.2% from the last close), with a high of $8.00 and a low of $1.50.
Only 2 firms rated IKT in the past 90 days, not enough for a consensus
Average 12-month target
$4.75
▲ 244.2% upside
Based on 2 analysts who set a price target on IKT in the past 90 days. The average target is $4.75, with a high of $8.00 and a low of $1.50, compared with the last close of $1.38.
Low $1.50Avg $4.75High $8.00
Blue marker: last close $1.38
Highest target$8.00
Average target$4.75
Lowest target$1.50
Latest rating changes
Chardan CapitalMaintained
Nov 12Hold$1.50
HC Wainwright & Co.Reiterated
Nov 12Buy$8
Chardan CapitalInitiated
Oct 13Hold$1.50
HC Wainwright & Co.Maintained
Aug 16Buy$5
OppenheimerInitiated
Jun 10Buy$5
Date
Firm
Action
Rating
Price target
Nov 12
Chardan Capital
Maintained
Hold
$1.50
Nov 12
HC Wainwright & Co.
Reiterated
Buy
$8
Oct 13
Chardan Capital
Initiated
Hold
$1.50
Aug 16
HC Wainwright & Co.
Maintained
Buy
$5
Jun 10
Oppenheimer
Initiated
Buy
$5
Loading…
Technical Analysis
IKT · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 13% below its 20 day and 34% below its 50 day average. It is 40% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 36), near oversold. The nearest support is the 52 week low at $1.37, and the nearest resistance the Pivot at $1.41.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 8.4%/day
Key levels
$2.6152 week high+89.1%
$2.07100 day average+50.0%
$1.93200 day average+39.9%
$1.8550 day average+34.1%
$1.70Swing high (Oct 29)+23.2%
$1.5520 day average+12.3%
$1.44Pivot R1+4.3%
$1.41Pivot+2.2%
$1.38Last close
$1.3752 week low−0.7%
$1.34Pivot S1−2.9%
Indicators
RSI (14)
36.10
Weak, oversold below 30
Neutral
MACD
-0.10
Above its signal line
Bullish
Stochastic
13.4
Near the bottom of its range
Oversold
ADX (14)
39.7
Trending down
Williams %R
-97.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-190.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−8.0%
Change over 10 sessions
Bearish
ATR (14)
$0.12
Typical daily range, 8.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityLow, 16.8%/day
Key levels
$2.6152 week high+89.1%
$2.07100 day average+50.0%
$1.93200 day average+39.9%
$1.8550 day average+34.1%
$1.70Swing high (Oct 29)+23.2%
$1.5520 day average+12.3%
$1.44Pivot R1+4.3%
$1.41Pivot+2.2%
$1.38Last close
$1.3752 week low−0.7%
$1.34Pivot S1−2.9%
Indicators
RSI (14)
31.62
Weak, oversold below 30
Neutral
MACD
-0.13
Below its signal line
Bearish
Stochastic
4.8
Near the bottom of its range
Oversold
ADX (14)
26.5
Trending down
Williams %R
-99.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-136.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−41.0%
Change over 10 sessions
Bearish
ATR (14)
$0.23
Typical daily range, 16.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IKT
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how IKT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow IKT usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IKT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IKT is in one of them and how their past IKT trades turned out.
Inhibikase Therapeutics is a pharmaceutical company developing treatments for pulmonary arterial hypertension, a rare and progressive disease that affects the blood vessels in the lungs. Its lead candidate, IKT-001, is an oral drug related to imatinib, a cancer medicine that has been used for many years. The company is running clinical trials of IKT-001 and has not yet sold a product. Its intended patients are people living with pulmonary arterial hypertension, and the company is based in Wilmington, Delaware.